SCYNEXIS Files Definitive Proxy for Reverse Stock Split to Maintain Nasdaq Listing

summarizeSummary

SCYNEXIS has filed its definitive proxy statement for a special meeting on May 19, 2026, seeking shareholder approval for a reverse stock split (1-for-5 to 1-for-10) to regain compliance with Nasdaq's minimum bid price requirement and avoid delisting.

check_boxKey Events · Corporate Governance and Compliance · SCYX

• Shareholder Vote Scheduled

  A special meeting of stockholders is scheduled for May 19, 2026, to vote on the proposed reverse stock split.

• Reverse Stock Split Proposed

  The Board seeks approval for an amendment to implement a reverse stock split at a ratio ranging from 1-for-5 to 1-for-10, at its discretion.

• Nasdaq Compliance Critical

  The primary purpose of the reverse stock split is to regain compliance with Nasdaq's $1.00 minimum bid price requirement by June 15, 2026, to prevent delisting.

• Authorized Shares to Decrease Proportionately

  The proposal includes a proportionate reduction in the number of authorized common shares based on the reverse stock split ratio.

auto_awesomeAnalysis · SCYX · Life Sciences

This definitive proxy statement confirms SCYNEXIS's plan to execute a reverse stock split, a critical step to maintain its listing on The Nasdaq Capital Market. While reverse splits are often viewed negatively as they don't change fundamental value and can sometimes lead to further price declines, this action is necessary to avoid delisting, which would severely impact liquidity and access to capital. The proposal also includes a proportionate reduction in authorized shares, which could mitigate future dilution compared to maintaining a high authorized share count post-split. Investors should monitor the outcome of the May 19th special meeting and the subsequent impact on the stock's trading price and Nasdaq compliance.